VANCOUVER, BC, May 26, 2021 /CNW/ – MYND Life Sciences Inc. (“ MYND“), a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce its shares have been approved for listing on the Canadian Securities Exchange (“CSE“). The Company’s shares will commence trading at market open on May 26, 2021, under the symbol ‘MYND’. “We are incredibly proud…

Source

Previous articleVirtual Reality and Psychedelic Synergy
Next articleCybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions